

8:30 am EST - 3:00 pm EST
Past Event
8:30 am - 3:00 pm EST
1775 Massachusetts Avenue, NW
Washington, DC
20036
The U.S. Food and Drug Administration (FDA) currently utilizes information from multiple sources to evaluate the safety of approved medical products. Active medical product surveillance is a new tool that will augment the Agency’s existing postmarket safety assessment process. Numerous issues make communicating active surveillance activities and associated findings challenging.
On November 17, the Engelberg Center for Health Care Reform hosted a one-day expert workshop to discuss issues pertaining to communication of medical product safety surveillance findings. Experts from both the private and public sectors discussed several topics including:
Samuel R. Bagenstos, Richard G. Frank, Kristi Martin, Rachel Sachs, Christen Linke Young
July 14, 2025
Christen Linke Young, Richard G. Frank, Rachel Sachs
July 9, 2025
Loren Adler, Samantha Crow, Matthew Fiedler, Richard G. Frank, Rahul Fernandez, Derek Lake, Robert Tyler Braun
July 7, 2025